BWM
GMAB icon

Braeburn Wealth Management’s Genmab GMAB Stock Holding History

Braeburn Wealth Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,196
Closed -$1.08M – 92
2025
Q4 		$1.08M Buy
+35,196
New +$1.1M 0.55% 34

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Braeburn Wealth Management's GMAB Position: Q1 2026 in Review

Braeburn Wealth Management sold out of Genmab (GMAB) in Q1 2026, closing a stake of 35,196 shares — an estimated $1.08M sold.

Braeburn Wealth Management first reported a position in GMAB in Q4 2025 and held it in 1 quarter. The position peaked at $1.08M in Q4 2025. 275 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Braeburn Wealth Management reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
  • Braeburn Wealth Management sold 35,196 Genmab shares in Q1 2026, an estimated $1.08M.
  • Braeburn Wealth Management first reported a position in Genmab in Q4 2025 and held it in 1 quarter.
  • Braeburn Wealth Management's Genmab position peaked at $1.08M in Q4 2025.
  • 275 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Braeburn Wealth Management's 13F filing for Q1 2026, filed 17 Apr 2026.